First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis

References

• SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• RenRMechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemiaNat Rev Cancer20055317218315719031
   PubMed Web of Science ®Google Scholar
• SilverRTWoolfSHHehlmannRAn evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyBlood19999451517153610477676
   PubMed Web of Science ®Google Scholar
• HochhausALarsonRAGuilhotFLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaN Engl J Med20173761091792728273028
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemiaBlood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• HehlmannRLausekerMJung-MunkwitzSTolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemiaJ Clin Oncol201129121634164221422420
   PubMed Web of Science ®Google Scholar
• DeiningerMWKopeckyKJRadichJPImatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaBr J Haematol2014164222323224383843
   PubMed Web of Science ®Google Scholar
• MughalTIRadichJPDeiningerMWChronic myeloid leukemia: reminiscences and dreamsHaematologica2016101554155827132280
   PubMed Web of Science ®Google Scholar
• SaglioGKimDWIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med2010362242251225920525993
   PubMed Web of Science ®Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• CortesJEDe SouzaCAAyalaMSwitching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trialLancet Haematol2016312e581e59127890073
   PubMed Web of Science ®Google Scholar
• YeungDTOsbornMPWhiteDLTIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsBlood2015125691592325519749
   PubMed Web of Science ®Google Scholar
• ShahNPGuilhotFCortesJELong-term outcome with dasat-inib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 studyBlood2014123152317232424569263
   PubMed Web of Science ®Google Scholar
• CortesJEGambacorti-PasseriniCDeiningerMWBosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leuke-mia: Results From the Randomized BFORE TrialJ Clin Oncol201836323123729091516
   PubMed Web of Science ®Google Scholar
• SasakiKKantarjianHJabbourEFrontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisHaematologica20161018e324e32727175025
   PubMed Web of Science ®Google Scholar
• HigginsJPAltmanDGGøtzschePCThe Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsBMJ2011343d592822008217
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• PreudhommeCGuilhotJNicoliniFEImatinib plus pegin-terferon alfa-2a in chronic myeloid leukemiaN Engl J Med2010363262511252121175313
   PubMed Web of Science ®Google Scholar
• CortesJEBaccaraniMGuilhotFPhase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJ Clin Oncol201028342443020008622
   PubMed Web of Science ®Google Scholar
• BaccaraniMRostiGCastagnettiFComparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European Leuke-miaNet StudyBlood2009113194497450419264678
   PubMed Web of Science ®Google Scholar
• Hjorth-HansenHStenkeLSöderlundSDasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Eur J Haematol201594324325025082346
   PubMed Web of Science ®Google Scholar
• RadichJPKopeckyKJAppelbaumFRA randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaBlood2012120193898390522915637
   PubMed Web of Science ®Google Scholar
• ZhouLWangJXHuangXJHuJDShenZXPreliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemiaZhonghua Xue Ye Xue Za Zhi2013342939723611212
   PubMedGoogle Scholar
• O’BrienSAdamsSForoniLSpirit 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CMLASH Annual Abstracts Meetings2014124517
   Google Scholar
• ShahNPFront-Line Treatment Options for Chronic-Phase Chronic Myeloid LeukemiaJ Clin Oncol201836322022429206554
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWKantarjianHMBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJ Clin Oncol201230283486349222949154
   PubMed Web of Science ®Google Scholar
• GurionRRaananiPVidalLLeaderAGafter-GviliAFirst line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response -systematic review and meta-analysisActa Oncol2016559–101077108327560448
   PubMed Web of Science ®Google Scholar
• ElsayedAGSrivastavaRJamilMOTreatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous LeukemiaCurr Oncol Rep201719127728988389
   PubMed Web of Science ®Google Scholar
• SaußeleSRichterJHochhausAMahonFXThe concept of treatment-free remission in chronic myeloid leukemiaLeukemia20163081638164727133824
   PubMed Web of Science ®Google Scholar
• HughesTPRossDMMoving treatment-free remission into mainstream clinical practice in CMLBlood20161281172327013442
   PubMed Web of Science ®Google Scholar
• FirwanaBSonbolMBDiabMTyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparisonInt J Cancer201613861545155326455714
   PubMed Web of Science ®Google Scholar
• RossDMMassziTGómez CasaresMTDurable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyJ Cancer Res Clin Oncol2018144594595429468438
   PubMed Web of Science ®Google Scholar
• ReaDNicoliniFETulliezMDiscontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyBlood2017129784685427932374
   PubMed Web of Science ®Google Scholar
• HochhausAMassziTGilesFJTreatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom studyLeukemia20173171525153128218239
   PubMed Web of Science ®Google Scholar
• MahonFXEtienneGDeep molecular response in chronic myeloid leukemia: the new goal of therapy?Clin Cancer Res201420231032224166905
   PubMed Web of Science ®Google Scholar
• CortesJEAbruzzeseEChelyshevaEThe impact of dasatinib on pregnancy outcomesAm J Hematol201590121111111526348106
   PubMed Web of Science ®Google Scholar
• HughesTPHochhausABranfordSLong-term prognostic signifi-cance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood2010116193758376520679528
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHMSaglioGEarly response with dasat-inib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Blood2014123449450024311723
   PubMed Web of Science ®Google Scholar
• HughesTPSaglioGKantarjianHMEarly molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinibBlood201412391353136024335106
   PubMed Web of Science ®Google Scholar
• JainPKantarjianHNazhaAEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesBlood2013121244867487423620574
   PubMed Web of Science ®Google Scholar
• NeelakantanPGerrardGLucasCCombining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategiesBlood2013121142739274223380743
   PubMed Web of Science ®Google Scholar
• SausseleSKraussMPHehlmannRSchweizerische Arbeitsge-meinschaft für Klinische Krebsforschung and the German CML Study GroupImpact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IVBlood20151261424925918346
   PubMed Web of Science ®Google Scholar
• ValentPHadzijusufovicESchernthanerGHWolfDReaDle CourtePVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsBlood2015125690190625525119
   PubMed Web of Science ®Google Scholar
• MontaniDBergotEGüntherSPulmonary arterial hypertension in patients treated by dasatinibCirculation2012125172128213722451584
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAHanXKantarjianHCortesJTyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaBlood2009114226126319414863
   PubMed Web of Science ®Google Scholar
• HochhausASaglioGHughesTPLong-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia20163051044105426837842
   PubMed Web of Science ®Google Scholar
• Pinilla-IbarzJCortesJMauroMJIntolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implicationsCancer2011117468869720922786
   PubMed Web of Science ®Google Scholar